(1) Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R. L.; Torre, L. A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer. J. Clin. 2018, 68, 394-424.
(2) Ferlay, J.; Colombet, M.; Soerjomataram, I.; Mathers, C.; Parkin, D. M.; Pineros, M.; Znaor, A.;
Bray, F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 2019, 144, 1941-1953.
(3) Robert-Koch-Institit Krebs in Deutschland 2011/2012; 2015; (abgerufen am: 23.03.2019).
(4) McGuire, S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv. Nutr. 2016, 7, 418-419.
(5) Al-Bayati, O.; Hasan, A.; Pruthi, D.; Kaushik, D.; Liss, M. A. Systematic review of modifiable risk factors for kidney cancer. Urol. Oncol. 2019, 37, 359-371.
(6) Fisher, R.; Gore, M.; Larkin, J. Current and future systemic treatments for renal cell carcinoma.
Semin. Cancer Biol. 2013, 23, 38-45.
(7) NCI, N. C. I. SEER, Cancer Stat Facts. 2016; (abgerufen am: 31.05.2019).
(8) Cohen, N. M.; Kenigsberg, E.; Tanay, A. Primate CpG islands are maintained by heterogeneous evolutionary regimes involving minimal selection. Cell 2011, 145, 773-786.
(9) Curtis, S. A.; Cohen, J. V.; Kluger, H. M. Evolving Immunotherapy Approaches for Renal Cell Carcinoma. Curr. Oncol. Rep. 2016, 18, 57.
(10) Reiter, I.; Krammer, B.; Schwamberger, G. Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities. J. Immunol. 1999, 163, 1730-1732.
(11) Cao, Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int. J. Biochem.
Cell Biol. 2001, 33, 357-369.
(12) Folkman, J. Endogenous angiogenesis inhibitors. APMIS 2004, 112, 496-507.
(13) Faivre, S.; Kroemer, G.; Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006, 5, 671-688.
(14) Vignot, S.; Faivre, S.; Aguirre, D.; Raymond, E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 2005, 16, 525-537.
(15) Tanneeru, K.; Guruprasad, L. Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors. J. Mol. Model. 2012, 18, 1611-1624.
(16) Keir, M. E.; Butte, M. J.; Freeman, G. J.; Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26, 677-704.
106 (17) Zarour, H. M. Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin. Cancer Res. 2016, 22, 1856-1864.
(18) Reiter, M. A. Nierenzellkarzinom Medikamentöse Therapie und prognostische Modelle.
Onkologe 2014, 12, 1241-1251.
(19) Albiges, L.; Oudard, S.; Negrier, S.; Caty, A.; Gravis, G.; Joly, F.; Duclos, B.; Geoffrois, L.;
Rolland, F.; Guillot, A.; Laguerre, B.; Legouffe, E.; Kohser, F.; Dietrich, P. Y.; Theodore, C. A.;
Escudier, B. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J. Clin.
Oncol. 2012, 30, 482-487.
(20) Procopio, G.; Verzoni, E.; Bracarda, S.; Ricci, S.; Sacco, C.; Ridolfi, L.; Porta, C.; Miceli, R.;
Zilembo, N.; Bajetta, E.; Italian Trials in Medical Oncology (ITMO) group Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. Ann. Oncol. 2013, 24, 2967-2971.
(21) Motzer, R. J.; Basch, E. Targeted drugs for metastatic renal cell carcinoma. Lancet 2007, 370, 2071-2073.
(22) Porta, C.; Sabbatini, R.; Procopio, G.; Paglino, C.; Galligioni, E.; Ortega, C. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev. Anticancer Ther. 2012, 12, 1571-1577.
(23) Seidel, C.; Busch, J.; Weikert, S.; Steffens, S.; Fenner, M.; Ganser, A.; Grunwald, V. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Eur. J. Cancer 2012, 48, 1023-1030.
(24) Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF) , der Deutschen Krebsgesellschaft e.V. (DKG) und der Deutschen Krebshilfe S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms. (abgerufen am: 31.05.2019)
(25) Pichler, M.; Hutterer, G. C.; Chromecki, T. F.; Jesche, J.; Kampel-Kettner, K.; Groselj-Strele, A.;
Hoefler, G.; Pummer, K.; Zigeuner, R. Comparison of the 2002 and 2010 TNM classification systems regarding outcome prediction in clear cell and papillary renal cell carcinoma. Histopathology 2013, 62, 237-246.
(26) Kim, H. L.; Han, K. R.; Zisman, A.; Figlin, R. A.; Belldegrun, A. S. Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J. Urol. 2004, 171, 1810-1813.
(27) Bensalah, K.; Leray, E.; Fergelot, P.; Rioux-Leclercq, N.; Tostain, J.; Guille, F.; Patard, J. J.
Prognostic value of thrombocytosis in renal cell carcinoma. J. Urol. 2006, 175, 859-863.
(28) Flanigan, R. C.; Polcari, A. J.; Hugen, C. M. Prognostic variables and nomograms for renal cell carcinoma. Int. J. Urol. 2011, 18, 20-31.
(29) Leibovich, B. C.; Lohse, C. M.; Crispen, P. L.; Boorjian, S. A.; Thompson, R. H.; Blute, M. L.;
Cheville, J. C. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J. Urol. 2010, 183, 1309-1315.
107 (30) Mekhail, T. M.; Abou-Jawde, R. M.; Boumerhi, G.; Malhi, S.; Wood, L.; Elson, P.; Bukowski, R.
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 2005, 23, 832-841.
(31) Heng, D. Y.; Xie, W.; Regan, M. M.; Warren, M. A.; Golshayan, A. R.; Sahi, C.; Eigl, B. J.;
Ruether, J. D.; Cheng, T.; North, S.; Venner, P.; Knox, J. J.; Chi, K. N.; Kollmannsberger, C.;
McDermott, D. F.; Oh, W. K.; Atkins, M. B.; Bukowski, R. M.; Rini, B. I.; Choueiri, T. K. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 2009, 27, 5794-5799.
(32) Heng, D. Y.; Xie, W.; Regan, M. M.; Harshman, L. C.; Bjarnason, G. A.; Vaishampayan, U. N.;
Mackenzie, M.; Wood, L.; Donskov, F.; Tan, M. H.; Rha, S. Y.; Agarwal, N.; Kollmannsberger, C.;
Rini, B. I.; Choueiri, T. K. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
Lancet Oncol. 2013, 14, 141-148.
(33) Galsky, M. D. A prognostic model for metastatic renal-cell carcinoma. Lancet Oncol. 2013, 14, 102-103.
(34) Linehan, W. M.; Ricketts, C. J. The metabolic basis of kidney cancer. Semin. Cancer Biol. 2013, 23, 46-55.
(35) Li, B.; Qiu, B.; Lee, D. S.; Walton, Z. E.; Ochocki, J. D.; Mathew, L. K.; Mancuso, A.; Gade, T.
P.; Keith, B.; Nissim, I.; Simon, M. C. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature 2014, 513, 251-255.
(36) Kelly, P. M.; Davison, R. S.; Bliss, E.; McGee, J. O. Macrophages in human breast disease: a quantitative immunohistochemical study. Br. J. Cancer 1988, 57, 174-177.
(37) Seliger, B.; Schlaf, G. Structure, expression and function of HLA-G in renal cell carcinoma.
Semin. Cancer Biol. 2007, 17, 444-450.
(38) Dunker, K.; Schlaf, G.; Bukur, J.; Altermann, W. W.; Handke, D.; Seliger, B. Expression and regulation of non-classical HLA-G in renal cell carcinoma. Tissue Antigens 2008, 72, 137-148.
(39) Noessner, E.; Brech, D.; Mendler, A. N.; Masouris, I.; Schlenker, R.; Prinz, P. U. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. Oncoimmunology 2012, 1, 1451-1453.
(40) Daurkin, I.; Eruslanov, E.; Stoffs, T.; Perrin, G. Q.; Algood, C.; Gilbert, S. M.; Rosser, C. J.; Su, L. M.; Vieweg, J.; Kusmartsev, S. Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res. 2011, 71, 6400-6409.
(41) Eruslanov, E.; Stoffs, T.; Kim, W. J.; Daurkin, I.; Gilbert, S. M.; Su, L. M.; Vieweg, J.; Daaka, Y.; Kusmartsev, S. Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas. Clin. Cancer Res. 2013, 19, 1670-1680.
108 (42) Xu, L.; Zhu, Y.; Chen, L.; An, H.; Zhang, W.; Wang, G.; Lin, Z.; Xu, J. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann. Surg. Oncol.
2014, 21, 3142-3150.
(43) Adeniran, A. J.; Shuch, B.; Humphrey, P. A. Hereditary Renal Cell Carcinoma Syndromes:
Clinical, Pathologic, and Genetic Features. Am. J. Surg. Pathol. 2015, 39, e1-e18.
(44) Al-Bayati, O.; Hasan, A.; Pruthi, D.; Kaushik, D.; Liss, M. A. Systematic review of modifiable risk factors for kidney cancer. Urol. Oncol. 2019.
(45) Desimone, M. C.; Rathmell, W. K.; Threadgill, D. W. Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response.
J. Natl. Cancer Inst. 2013, 105, 1355-1364.
(46) Frew, I. J.; Moch, H. A clearer view of the molecular complexity of clear cell renal cell carcinoma. Annu. Rev. Pathol. 2015, 10, 263-289.
(47) Dalgliesh, G. L.; Furge, K.; Greenman, C.; Chen, L.; Bignell, G.; Butler, A.; Davies, H.; Edkins, S.; Hardy, C.; Latimer, C.; Teague, J.; Andrews, J.; Barthorpe, S.; Beare, D.; Buck, G.; Campbell, P.
J.; Forbes, S.; Jia, M.; Jones, D.; Knott, H.; Kok, C. Y.; Lau, K. W.; Leroy, C.; Lin, M. L.; McBride, D. J.; Maddison, M.; Maguire, S.; McLay, K.; Menzies, A.; Mironenko, T.; Mulderrig, L.; Mudie, L.;
O'Meara, S.; Pleasance, E.; Rajasingham, A.; Shepherd, R.; Smith, R.; Stebbings, L.; Stephens, P.;
Tang, G.; Tarpey, P. S.; Turrell, K.; Dykema, K. J.; Khoo, S. K.; Petillo, D.; Wondergem, B.; Anema, J.; Kahnoski, R. J.; Teh, B. T.; Stratton, M. R.; Futreal, P. A. Systematic sequencing of renal
carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463, 360-363.
(48) Bihr, S.; Ohashi, R.; Moore, A. L.; Ruschoff, J. H.; Beisel, C.; Hermanns, T.; Mischo, A.; Corro, C.; Beyer, J.; Beerenwinkel, N.; Moch, H.; Schraml, P. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Neoplasia 2019, 21, 247-256.
(49) Turajlic, S.; Xu, H.; Litchfield, K.; Rowan, A.; Horswell, S.; Chambers, T.; O'Brien, T.; Lopez, J.
I.; Watkins, T. B. K.; Nicol, D.; Stares, M.; Challacombe, B.; Hazell, S.; Chandra, A.; Mitchell, T. J.;
Au, L.; Eichler-Jonsson, C.; Jabbar, F.; Soultati, A.; Chowdhury, S.; Rudman, S.; Lynch, J.; Fernando, A.; Stamp, G.; Nye, E.; Stewart, A.; Xing, W.; Smith, J. C.; Escudero, M.; Huffman, A.; Matthews, N.; Elgar, G.; Phillimore, B.; Costa, M.; Begum, S.; Ward, S.; Salm, M.; Boeing, S.; Fisher, R.; Spain, L.; Navas, C.; Gronroos, E.; Hobor, S.; Sharma, S.; Aurangzeb, I.; Lall, S.; Polson, A.; Varia, M.;
Horsfield, C.; Fotiadis, N.; Pickering, L.; Schwarz, R. F.; Silva, B.; Herrero, J.; Luscombe, N. M.;
Jamal-Hanjani, M.; Rosenthal, R.; Birkbak, N. J.; Wilson, G. A.; Pipek, O.; Ribli, D.; Krzystanek, M.;
Csabai, I.; Szallasi, Z.; Gore, M.; McGranahan, N.; Van Loo, P.; Campbell, P.; Larkin, J.; Swanton, C.; TRACERx Renal Consortium Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell 2018, 173, 595-610.e11.
(50) Brugarolas, J. Molecular genetics of clear-cell renal cell carcinoma. J. Clin. Oncol. 2014, 32, 1968-1976.
(51) Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499, 43-49.
109 (52) Varela, I.; Tarpey, P.; Raine, K.; Huang, D.; Ong, C. K.; Stephens, P.; Davies, H.; Jones, D.; Lin, M. L.; Teague, J.; Bignell, G.; Butler, A.; Cho, J.; Dalgliesh, G. L.; Galappaththige, D.; Greenman, C.;
Hardy, C.; Jia, M.; Latimer, C.; Lau, K. W.; Marshall, J.; McLaren, S.; Menzies, A.; Mudie, L.;
Stebbings, L.; Largaespada, D. A.; Wessels, L. F.; Richard, S.; Kahnoski, R. J.; Anema, J.; Tuveson, D. A.; Perez-Mancera, P. A.; Mustonen, V.; Fischer, A.; Adams, D. J.; Rust, A.; Chan-on, W.;
Subimerb, C.; Dykema, K.; Furge, K.; Campbell, P. J.; Teh, B. T.; Stratton, M. R.; Futreal, P. A.
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469, 539-542.
(53) Domazet-Loso, T.; Tautz, D. Phylostratigraphic tracking of cancer genes suggests a link to the emergence of multicellularity in metazoa. BMC Biol. 2010, 8:66.
(54) Gerlinger, M.; Horswell, S.; Larkin, J.; Rowan, A. J.; Salm, M. P.; Varela, I.; Fisher, R.;
McGranahan, N.; Matthews, N.; Santos, C. R.; Martinez, P.; Phillimore, B.; Begum, S.; Rabinowitz, A.; Spencer-Dene, B.; Gulati, S.; Bates, P. A.; Stamp, G.; Pickering, L.; Gore, M.; Nicol, D. L.;
Hazell, S.; Futreal, P. A.; Stewart, A.; Swanton, C. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 2014, 46, 225-233.
(55) Huang, Y.; Wang, J.; Jia, P.; Li, X.; Pei, G.; Wang, C.; Fang, X.; Zhao, Z.; Cai, Z.; Yi, X.; Wu, S.; Zhang, B. Clonal architectures predict clinical outcome in clear cell renal cell carcinoma. Nat.
Commun. 2019, 10(1):1245.
(56) Gerlinger, M.; Rowan, A. J.; Horswell, S.; Math, M.; Larkin, J.; Endesfelder, D.; Gronroos, E.;
Martinez, P.; Matthews, N.; Stewart, A.; Tarpey, P.; Varela, I.; Phillimore, B.; Begum, S.; McDonald, N. Q.; Butler, A.; Jones, D.; Raine, K.; Latimer, C.; Santos, C. R.; Nohadani, M.; Eklund, A. C.;
Spencer-Dene, B.; Clark, G.; Pickering, L.; Stamp, G.; Gore, M.; Szallasi, Z.; Downward, J.; Futreal, P. A.; Swanton, C. Intratumor heterogeneity and branched evolution revealed by multiregion
sequencing. N. Engl. J. Med. 2012, 366, 883-892.
(57) Sanfrancesco, J. M.; Cheng, L. Complexity of the genomic landscape of renal cell carcinoma:
Implications for targeted therapy and precision immuno-oncology. Crit. Rev. Oncol. Hematol. 2017, 119, 23-28.
(58) Sato, Y.; Yoshizato, T.; Shiraishi, Y.; Maekawa, S.; Okuno, Y.; Kamura, T.; Shimamura, T.;
Sato-Otsubo, A.; Nagae, G.; Suzuki, H.; Nagata, Y.; Yoshida, K.; Kon, A.; Suzuki, Y.; Chiba, K.;
Tanaka, H.; Niida, A.; Fujimoto, A.; Tsunoda, T.; Morikawa, T.; Maeda, D.; Kume, H.; Sugano, S.;
Fukayama, M.; Aburatani, H.; Sanada, M.; Miyano, S.; Homma, Y.; Ogawa, S. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 2013, 45, 860-867.
(59) Cancer Genome Atlas Research Network; Weinstein, J. N.; Collisson, E. A.; Mills, G. B.; Shaw, K. R.; Ozenberger, B. A.; Ellrott, K.; Shmulevich, I.; Sander, C.; Stuart, J. M. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 2013, 45, 1113-1120.
(60) Joosten, S. C.; Smits, K. M.; Aarts, M. J.; Melotte, V.; Koch, A.; Tjan-Heijnen, V. C.; van Engeland, M. Epigenetics in renal cell cancer: mechanisms and clinical applications. Nat. Rev. Urol.
2018, 15, 430-451.
110 (61) Schimansky, I. Subtypspezifische DNA-Methylierung von CDH3 (P-Cadeherin) in humanen Nierenzellkarzinomen[dissertation]. Hannover: Medizinische Hochshule Hannover; 2011.
(62) Ding, L.; Ellis, M. J.; Li, S.; Larson, D. E.; Chen, K.; Wallis, J. W.; Harris, C. C.; McLellan, M.
D.; Fulton, R. S.; Fulton, L. L.; Abbott, R. M.; Hoog, J.; Dooling, D. J.; Koboldt, D. C.; Schmidt, H.;
Kalicki, J.; Zhang, Q.; Chen, L.; Lin, L.; Wendl, M. C.; McMichael, J. F.; Magrini, V. J.; Cook, L.;
McGrath, S. D.; Vickery, T. L.; Appelbaum, E.; Deschryver, K.; Davies, S.; Guintoli, T.; Lin, L.;
Crowder, R.; Tao, Y.; Snider, J. E.; Smith, S. M.; Dukes, A. F.; Sanderson, G. E.; Pohl, C. S.;
Delehaunty, K. D.; Fronick, C. C.; Pape, K. A.; Reed, J. S.; Robinson, J. S.; Hodges, J. S.; Schierding, W.; Dees, N. D.; Shen, D.; Locke, D. P.; Wiechert, M. E.; Eldred, J. M.; Peck, J. B.; Oberkfell, B. J.;
Lolofie, J. T.; Du, F.; Hawkins, A. E.; O'Laughlin, M. D.; Bernard, K. E.; Cunningham, M.; Elliott, G.; Mason, M. D.; Thompson, D. M.,Jr; Ivanovich, J. L.; Goodfellow, P. J.; Perou, C. M.; Weinstock, G. M.; Aft, R.; Watson, M.; Ley, T. J.; Wilson, R. K.; Mardis, E. R. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464, 999-1005.
(63) Yachida, S.; Jones, S.; Bozic, I.; Antal, T.; Leary, R.; Fu, B.; Kamiyama, M.; Hruban, R. H.;
Eshleman, J. R.; Nowak, M. A.; Velculescu, V. E.; Kinzler, K. W.; Vogelstein, B.; Iacobuzio-Donahue, C. A. Distant metastasis occurs late during the genetic evolution of pancreatic cancer.
Nature 2010, 467, 1114-1117.
(64) Tao, Y.; Ruan, J.; Yeh, S. H.; Lu, X.; Wang, Y.; Zhai, W.; Cai, J.; Ling, S.; Gong, Q.; Chong, Z.;
Qu, Z.; Li, Q.; Liu, J.; Yang, J.; Zheng, C.; Zeng, C.; Wang, H. Y.; Zhang, J.; Wang, S. H.; Hao, L.;
Dong, L.; Li, W.; Sun, M.; Zou, W.; Yu, C.; Li, C.; Liu, G.; Jiang, L.; Xu, J.; Huang, H.; Li, C.; Mi, S.; Zhang, B.; Chen, B.; Zhao, W.; Hu, S.; Zhuang, S. M.; Shen, Y.; Shi, S.; Brown, C.; White, K. P.;
Chen, D. S.; Chen, P. J.; Wu, C. I. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc. Natl. Acad. Sci.
U. S. A. 2011, 108, 12042-12047.
(65) Hofflin, R.; Roth, W.; Sultmann, H.; Grullich, C.; Hatiboglu, G.; Nyarangi-Dix, J.; Schonberg, G.; Teber, D.; Hadaschik, B.; Pahernik, S.; Hohenfellner, M.; Duensing, S. Intratumoral heterogeneity in renal cell carcinoma. Molecular basis and translational implications. Urologe A. 2015, 54, 800-803.
(66) Klatte, T.; Rao, P. N.; de Martino, M.; LaRochelle, J.; Shuch, B.; Zomorodian, N.; Said, J.;
Kabbinavar, F. F.; Belldegrun, A. S.; Pantuck, A. J. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J. Clin. Oncol. 2009, 27, 746-753.
(67) Parker, A. S.; Leibovich, B. C.; Lohse, C. M.; Sheinin, Y.; Kuntz, S. M.; Eckel-Passow, J. E.;
Blute, M. L.; Kwon, E. D. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009, 115, 2092-2103.
(68) Monzon, F. A.; Alvarez, K.; Peterson, L.; Truong, L.; Amato, R. J.; Hernandez-McClain, J.;
Tannir, N.; Parwani, A. V.; Jonasch, E. Chromosome 14q loss defines a molecular subtype of clear-cell renal clear-cell carcinoma associated with poor prognosis. Mod. Pathol. 2011, 24, 1470-1479.
(69) Sanjmyatav, J.; Junker, K.; Matthes, S.; Muehr, M.; Sava, D.; Sternal, M.; Wessendorf, S.; Kreuz, M.; Gajda, M.; Wunderlich, H.; Schwaenen, C. Identification of genomic alterations associated with
111 metastasis and cancer specific survival in clear cell renal cell carcinoma. J. Urol. 2011, 186, 2078-2083.
(70) Eichelberg, C.; Chun, F. K.; Bedke, J.; Heuer, R.; Adam, M.; Moch, H.; Terracciano, L.;
Hinrichs, K.; Dahlem, R.; Fisch, M.; Schlomm, T.; Sauter, G.; Minner, S. Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. Int. J. Cancer 2013, 132, 2948-2955.
(71) Divgi, C. R.; Uzzo, R. G.; Gatsonis, C.; Bartz, R.; Treutner, S.; Yu, J. Q.; Chen, D.; Carrasquillo, J. A.; Larson, S.; Bevan, P.; Russo, P. Positron emission tomography/computed tomography
identification of clear cell renal cell carcinoma: results from the REDECT trial. J. Clin. Oncol. 2013, 31, 187-194.
(72) Farber, N. J.; Wu, Y.; Zou, L.; Belani, P.; Singer, E. A. Challenges in RCC Imaging: Renal Insufficiency, Post-Operative Surveillance, and the Role of Radiomics. Kidney Cancer. J. 2015, 13, 84-90.
(73) Rowe, S. P.; Gorin, M. A.; Hammers, H. J.; Som Javadi, M.; Hawasli, H.; Szabo, Z.; Cho, S. Y.;
Pomper, M. G.; Allaf, M. E. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (1)(8)F-DCFPyL PET/CT. Ann. Nucl. Med. 2015, 29, 877-882.
(74) Morrissey, J. J.; Mellnick, V. M.; Luo, J.; Siegel, M. J.; Figenshau, R. S.; Bhayani, S.; Kharasch, E. D. Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study. JAMA Oncol. 2015, 1, 204-212.
(75) Ball, M. W.; Gorin, M. A.; Guner, G.; Pierorazio, P. M.; Netto, G.; Paller, C. J.; Hammers, H. J.;
Diaz, L. A.; Allaf, M. E. Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study. Clin. Genitourin. Cancer. 2016, 14, e515-e520.
(76) Gatto, F.; Maruzzo, M.; Magro, C.; Basso, U.; Nielsen, J. Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma. Front. Oncol. 2016, 6, 253.
(77) Pena, C.; Lathia, C.; Shan, M.; Escudier, B.; Bukowski, R. M. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin. Cancer Res. 2010, 16, 4853-4863.
(78) Armstrong, A. J.; George, D. J.; Halabi, S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J. Clin. Oncol. 2012, 30, 3402-3407.
(79) Tran, H. T.; Liu, Y.; Zurita, A. J.; Lin, Y.; Baker-Neblett, K. L.; Martin, A. M.; Figlin, R. A.;
Hutson, T. E.; Sternberg, C. N.; Amado, R. G.; Pandite, L. N.; Heymach, J. V. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012, 13, 827-837.
(80) Zurita, A. J.; Jonasch, E.; Wang, X.; Khajavi, M.; Yan, S.; Du, D. Z.; Xu, L.; Herynk, M. H.;
McKee, K. S.; Tran, H. T.; Logothetis, C. J.; Tannir, N. M.; Heymach, J. V. A cytokine and
112 angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with
metastatic renal cell carcinoma. Ann. Oncol. 2012, 23, 46-52.
(81) Hegde, P. S.; Jubb, A. M.; Chen, D.; Li, N. F.; Meng, Y. G.; Bernaards, C.; Elliott, R.; Scherer, S.
J.; Chen, D. S. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin. Cancer Res. 2013, 19, 929-937.
(82) Funakoshi, T.; Lee, C. H.; Hsieh, J. J. A systematic review of predictive and prognostic
biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treat. Rev. 2014, 40, 533-547.
(83) Pawlowski, R.; Muhl, S. M.; Sulser, T.; Krek, W.; Moch, H.; Schraml, P. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int. J. Cancer 2013, 132, E11-17.
(84) Heinzelmann, J.; Henning, B.; Sanjmyatav, J.; Posorski, N.; Steiner, T.; Wunderlich, H.; Gajda, M. R.; Junker, K. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J. Urol. 2011, 29, 367-373.
(85) Slaby, O.; Redova, M.; Poprach, A.; Nekvindova, J.; Iliev, R.; Radova, L.; Lakomy, R.; Svoboda, M.; Vyzula, R. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer 2012, 51, 707-716.
(86) Fritz, H. K.; Lindgren, D.; Ljungberg, B.; Axelson, H.; Dahlback, B. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. Eur. J. Cancer 2014, 50, 1758-1765.
(87) Nofech-Mozes, R.; Khella, H. W.; Scorilas, A.; Youssef, L.; Krylov, S. N.; Lianidou, E.;
Sidiropoulos, K. G.; Gabril, M.; Evans, A.; Yousef, G. M. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma. Cancer. Med. 2016, 5, 656-664.
(88) Hildebrandt, M. A.; Gu, J.; Lin, J.; Ye, Y.; Tan, W.; Tamboli, P.; Wood, C. G.; Wu, X. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010, 29, 5724-5728.
(89) Fabrizio, F. P.; Costantini, M.; Copetti, M.; la Torre, A.; Sparaneo, A.; Fontana, A.; Poeta, L.;
Gallucci, M.; Sentinelli, S.; Graziano, P.; Parente, P.; Pompeo, V.; De Salvo, L.; Simone, G.; Papalia, R.; Picardo, F.; Balsamo, T.; Flammia, G. P.; Trombetta, D.; Pantalone, A.; Kok, K.; Paranita, F.;
Muscarella, L. A.; Fazio, V. M. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. Oncotarget 2017, 8, 11187-11198.
(90) Kapur, P.; Pena-Llopis, S.; Christie, A.; Zhrebker, L.; Pavia-Jimenez, A.; Rathmell, W. K.; Xie, X. J.; Brugarolas, J. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 2013, 14, 159-167.
(91) Tian, Y.; Arai, E.; Gotoh, M.; Komiyama, M.; Fujimoto, H.; Kanai, Y. Prognostication of patients with clear cell renal cell carcinomas based on quantification of DNA methylation levels of CpG island methylator phenotype marker genes. BMC Cancer 2014, 14, 772.
(92) Lin, Y. L.; Wang, Y. P.; Li, H. Z.; Zhang, X. Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma. Med. Sci. Monit.
2017, 23, 3318-3323.
113 (93) Ito, N.; Eto, M.; Nakamura, E.; Takahashi, A.; Tsukamoto, T.; Toma, H.; Nakazawa, H.; Hirao, Y.; Uemura, H.; Kagawa, S.; Kanayama, H.; Nose, Y.; Kinukawa, N.; Nakamura, T.; Jinnai, N.; Seki, T.; Takamatsu, M.; Masui, Y.; Naito, S.; Ogawa, O. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2007, 25, 2785-2791.
(94) Garcia-Donas, J.; Esteban, E.; Leandro-Garcia, L. J.; Castellano, D. E.; del Alba, A. G.; Climent, M. A.; Arranz, J. A.; Gallardo, E.; Puente, J.; Bellmunt, J.; Mellado, B.; Martinez, E.; Moreno, F.;
Font, A.; Robledo, M.; Rodriguez-Antona, C. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011, 12, 1143-1150.
(95) Jonasch, E.; McCutcheon, I. E.; Waguespack, S. G.; Wen, S.; Davis, D. W.; Smith, L. A.; Tannir, N. M.; Gombos, D. S.; Fuller, G. N.; Matin, S. F. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann. Oncol. 2011, 22, 2661-2666.
(96) van der Veldt, A. A.; Eechoute, K.; Gelderblom, H.; Gietema, J.; Guchelaar, H. J.; van Erp, N. P.;
van den Eertwegh, A. J.; Haanen, J. B.; Mathijssen, R. H.; Wessels, J. A. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin. Cancer Res. 2011, 17, 620-629.
(97) Xu, C. F.; Bing, N. X.; Ball, H. A.; Rajagopalan, D.; Sternberg, C. N.; Hutson, T. E.; de Souza, P.; Xue, Z. G.; McCann, L.; King, K. S.; Ragone, L. J.; Whittaker, J. C.; Spraggs, C. F.; Cardon, L. R.;
Mooser, V. E.; Pandite, L. N. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J. Clin. Oncol. 2011, 29, 2557-2564.
(98) Kim, H. C.; Lee, J. S.; Kim, S. H.; So, H. S.; Woo, C. Y.; Lee, J. L. Sunitinib treatment for metastatic renal cell carcinoma in patients with von hippel-lindau disease. Cancer. Res. Treat. 2013, 45, 349-353.
(99) Cho, D.; Signoretti, S.; Dabora, S.; Regan, M.; Seeley, A.; Mariotti, M.; Youmans, A.; Polivy, A.;
Mandato, L.; McDermott, D.; Stanbridge, E.; Atkins, M. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer.
2007, 5, 379-385.
(100) Nishikawa, M.; Miyake, H.; Harada, K.; Fujisawa, M. Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors. Med. Oncol.
2014, 31, 792. Epub 2013 Dec 4.
(101) Morris, M. R.; Ricketts, C.; Gentle, D.; Abdulrahman, M.; Clarke, N.; Brown, M.; Kishida, T.;
Yao, M.; Latif, F.; Maher, E. R. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 2010, 29, 2104-2117.
(102) Deckers, I. A.; Schouten, L. J.; Van Neste, L.; van Vlodrop, I. J.; Soetekouw, P. M.; Baldewijns, M. M.; Jeschke, J.; Ahuja, N.; Herman, J. G.; van den Brandt, P. A.; van Engeland, M. Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.
Clin. Cancer Res. 2015, 21, 3492-3500.
114 (103) van Vlodrop, I. J.; Baldewijns, M. M.; Smits, K. M.; Schouten, L. J.; van Neste, L.; van
Criekinge, W.; van Poppel, H.; Lerut, E.; Schuebel, K. E.; Ahuja, N.; Herman, J. G.; de Bruine, A. P.;
van Engeland, M. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. Am. J. Pathol. 2010, 176, 575-584.
(104) Peters, I.; Eggers, H.; Atschekzei, F.; Hennenlotter, J.; Waalkes, S.; Trankenschuh, W.;
Grosshennig, A.; Merseburger, A. S.; Stenzl, A.; Kuczyk, M. A.; Serth, J. GATA5 CpG island
methylation in renal cell cancer: a potential biomarker for metastasis and disease progression. BJU Int.
2012, 110, E144-52.
(105) Agathanggelou, A.; Cooper, W. N.; Latif, F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005, 65, 3497-3508.
(106) Serth, J.; Tezval, H.; Peters, I.; Atschekzei, F.; Rehmet, K.; Jurk, S.; Albrecht, K.; Kuczyk, M.
A.; Merseburger, A. S. Methylation of the RASSF1A tumor suppressor gene promoter. Risk factor for carcinogenesis of urological tumors. Urologe A. 2008, 47, 1117-1120.
(107) Tezval, H.; Merseburger, A. S.; Matuschek, I.; Machtens, S.; Kuczyk, M. A.; Serth, J.
RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma. BMC Urol. 2008, 8:12.
(108) Atschekzei, F.; Hennenlotter, J.; Janisch, S.; Grosshennig, A.; Trankenschuh, W.; Waalkes, S.;
Peters, I.; Dork, T.; Merseburger, A. S.; Stenzl, A.; Kuczyk, M. A.; Serth, J. SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence.
Epigenetics 2012, 7, 447-457.
(109) Evelonn, E. A.; Landfors, M.; Haider, Z.; Kohn, L.; Ljungberg, B.; Roos, G.; Degerman, S.
DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma. BMC Cancer 2019, 19(1):65.
(110) Bird, A. P. DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids Res.
1980, 8, 1499-1504.
(111) Fazzari, M. J.; Greally, J. M. Epigenomics: beyond CpG islands. Nat. Rev. Genet. 2004, 5, 446-455.
(112) Wood, L. D.; Parsons, D. W.; Jones, S.; Lin, J.; Sjoblom, T.; Leary, R. J.; Shen, D.; Boca, S. M.;
Barber, T.; Ptak, J.; Silliman, N.; Szabo, S.; Dezso, Z.; Ustyanksky, V.; Nikolskaya, T.; Nikolsky, Y.;
Karchin, R.; Wilson, P. A.; Kaminker, J. S.; Zhang, Z.; Croshaw, R.; Willis, J.; Dawson, D.; Shipitsin, M.; Willson, J. K.; Sukumar, S.; Polyak, K.; Park, B. H.; Pethiyagoda, C. L.; Pant, P. V.; Ballinger, D.
G.; Sparks, A. B.; Hartigan, J.; Smith, D. R.; Suh, E.; Papadopoulos, N.; Buckhaults, P.; Markowitz, S.
D.; Parmigiani, G.; Kinzler, K. W.; Velculescu, V. E.; Vogelstein, B. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318, 1108-1113.
(113) Chen, R. Z.; Pettersson, U.; Beard, C.; Jackson-Grusby, L.; Jaenisch, R. DNA hypomethylation leads to elevated mutation rates. Nature 1998, 395, 89-93.
115 (114) Schuebel, K. E.; Chen, W.; Cope, L.; Glockner, S. C.; Suzuki, H.; Yi, J. M.; Chan, T. A.; Van Neste, L.; Van Criekinge, W.; van den Bosch, S.; van Engeland, M.; Ting, A. H.; Jair, K.; Yu, W.;
Toyota, M.; Imai, K.; Ahuja, N.; Herman, J. G.; Baylin, S. B. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 2007, 3, 1709-1723.
(115) Chan, T. A.; Glockner, S.; Yi, J. M.; Chen, W.; Van Neste, L.; Cope, L.; Herman, J. G.;
Velculescu, V.; Schuebel, K. E.; Ahuja, N.; Baylin, S. B. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med. 2008,5(5):
e114.
(116) Yi, J. M.; Dhir, M.; Van Neste, L.; Downing, S. R.; Jeschke, J.; Glockner, S. C.; de Freitas Calmon, M.; Hooker, C. M.; Funes, J. M.; Boshoff, C.; Smits, K. M.; van Engeland, M.; Weijenberg, M. P.; Iacobuzio-Donahue, C. A.; Herman, J. G.; Schuebel, K. E.; Baylin, S. B.; Ahuja, N. Genomic
(116) Yi, J. M.; Dhir, M.; Van Neste, L.; Downing, S. R.; Jeschke, J.; Glockner, S. C.; de Freitas Calmon, M.; Hooker, C. M.; Funes, J. M.; Boshoff, C.; Smits, K. M.; van Engeland, M.; Weijenberg, M. P.; Iacobuzio-Donahue, C. A.; Herman, J. G.; Schuebel, K. E.; Baylin, S. B.; Ahuja, N. Genomic